AmirAli is Co-Chief Executive Officer of Guardant Health. He is an entrepreneur in the rare genomics and clinical diagnostics fields. Prior to co-founding Guardant, he was Senior Director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next- generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. During his academic years, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University.
